Hitting up to drug discovery, PM Modi reviews India's vaccine development, diagnosis, testing for COVID-19

New Delhi, May 6: Reviewing the current status of India’s efforts in vaccine development, drug discovery, diagnosis and testing, Prime Minister Anrendra Modi on Wednesday chaired a meeting of the Task Force on Corona Vaccine Development. PM took note of the extraordinary coming together of academia, industry and government, combined with speedy but efficient regulatory process.

 

Emphasizing over what is possible in a crisis should be a part of our routine way of scientific functioning, PM Modi further desired that such coordination and speed should be embedded into a standard operating procedure. Appreciating the scientific coming together of computer science, chemistry and biotechnology in drug discovery, the PM suggested that a hackathon be held on this subject, linking computer science to synthesis and testing in the laboratory. The successful candidates from the hackathon could be taken up by the start-ups for further development and scaling up.

 

 

The PM added that the innovative and original manner in which Indian scientists, from basic to applied sciences, have come together with industry is heartening. This kind of pride, originality and sense of purpose should dominate our approach going ahead. It is only then that we can be amongst the best in the world and not followers, in science.

 

Indian vaccine companies are well known for their quality, manufacturing capacity and global presence. Today in addition, they have come across as innovators in early stage vaccine development research. Similarly, Indian academia and start-ups have also pioneered in this area. Over 30 Indian vaccines are in different stages of corona vaccine development, with a few going on to the trial stages.

Similarly, in drug development three approaches are being taken. First, the repurposing of existing drugs. At least four drugs are undergoing synthesis and examination in this category. Secondly, the development of new candidate drugs and molecules are being driven by linking high performance computational approached with laboratory verification. Thirdly, plant extracts and products are being examined for general anti-viral properties.

 

In diagnosis and testing, several academic research institutions and start-ups have developed new tests, both for the RT-PCR approach and for the antibody detection. The problem of importing reagents for testing has been addressed by consortia of Indian start-ups and industry, meeting current requirements. The current thrust also holds promise for the development of a robust long-term industry in this area.